The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis.

Atherosclerosis involves a complex array of factors, including leukocyte adhesion and platelet vasoactive factors. Aspirin, which is used to prevent secondary complications of atherosclerosis, inhibits platelet production of thromboxane (Tx) A(2). The actions of TxA(2) as well as of other arachidonic acid products, such as prostaglandin (PG) H(2), PGF(2alpha), hydroxyeicosatetraenoic acids, and isoprostanes, can be effectively antagonized by blocking thromboxane (TP) receptors. The purpose of this study was to determine the role of platelet-derived TxA(2) in atherosclerotic lesion development by comparing the effects of aspirin and the TP receptor antagonist S18886. The effect of 11 weeks of treatment with aspirin (30 mg. kg(-1). d(-1)) or S18886 (5 mg. kg(-1). d(-1)) on aortic root atherosclerotic lesions, serum levels of intercellular adhesion molecule-1 (ICAM-1), and the TxA(2) metabolite TxB(2) was determined in apolipoprotein E-deficient mice at 21 weeks of age. Both treatments did not affect body or heart weight or serum cholesterol levels. Aspirin, to a greater extent than S18886, significantly decreased serum TxB(2) levels, indicating the greater efficacy of aspirin in preventing platelet synthesis of TxA(2). S18886, but not aspirin, significantly decreased aortic root lesions as well as serum ICAM-1 levels. S18886 also prevented the increased expression of ICAM-1 in cultured human endothelial cells stimulated by the TP receptor agonist U46619. These results indicate that inhibition of platelet TxA(2) synthesis with aspirin has no significant effect on atherogenesis or adhesion molecule levels. The effects of S18886 suggest that blockade of TP receptors inhibits atherosclerosis by a mechanism independent of platelet-derived TxA(2), perhaps by preventing the expression of adhesion molecules whose expression is stimulated by eicosanoids other than TxA(2).

[1]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[2]  J. Maclouf,et al.  The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis. , 1999, The Journal of clinical investigation.

[3]  D. Rader,et al.  Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice , 1998, Nature Medicine.

[4]  J. Maclouf.  Recent advances in prostaglandin, thromboxane, and leukotriene research , 1998 .

[5]  Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists. , 1998, Bioorganic & medicinal chemistry letters.

[6]  E. Gonzalez,et al.  Antiplatelet therapy in atherosclerotic cardiovascular disease. , 1998, Clinical therapeutics.

[7]  G. FitzGerald,et al.  Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[8]  G. Lavielle,et al.  S 18886, a new thromboxane (TP)-receptor antagonist is the active isomer of S 18204 in all species, except in the guinea-pig. , 1997, Advances in experimental medicine and biology.

[9]  J. Vane,et al.  Recent Advances in Prostaglandin, Thromboxane, and Leukotriene Research , 1997, Advances in Experimental Medicine and Biology.

[10]  M. Milani,et al.  Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. , 2003, British journal of clinical pharmacology.

[11]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[12]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[13]  T. Hidaka,et al.  Thromboxane A2 receptor blockade suppresses intercellular adhesion molecule-1 expression by stimulated vascular endothelial cells. , 1996, European journal of pharmacology.

[14]  V. Kalra,et al.  Lipoxygenase metabolites induced expression of adhesion molecules and transendothelial migration of monocyte‐like HL‐60 cells is linked to protein kinase C activation , 1996, Journal of cellular physiology.

[15]  A. Herman,et al.  Influence of hypercholesterolaemia on the reactivity of isolated rabbit arteries to 15-lipoxygenase metabolites of arachidonic acid: comparison with platelet-derived agents and vasodilators. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[16]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[17]  R. Cohen,et al.  15‐Hydroxyeicosatetraenoic Acid and Diabetic Endothelial Dysfunction in Rabbit Aorta , 1995, Journal of cardiovascular pharmacology.

[18]  F. Violi,et al.  Effect of Picotamide on the Clinical Progression of Peripheral Vascular Disease A Double‐Blind Placebo‐Controlled Study , 1993 .

[19]  D. Dewitt,et al.  Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. , 1993, The Journal of biological chemistry.

[20]  W. Campbell,et al.  Characterization of arachidonic acid metabolism in Watanabe heritable hyperlipidemic (WHHL) and New Zealand white (NZW) rabbit aortas. , 1988, Prostaglandins.

[21]  A. Lefer,et al.  Cardioprotective actions of thromboxane receptor antagonism in ischemic atherosclerotic rabbits. , 1988, The American journal of physiology.

[22]  R. Williams,et al.  Quantitative assessment of atherosclerotic lesions in mice. , 1987, Atherosclerosis.

[23]  I. Juhan-vague,et al.  Comparison of the effects of aspirin and indomethacin on aortic atherogenesis induced in rabbits. , 1982, Atherosclerosis.

[24]  A. Makheja,et al.  Anti-inflammatory drugs in experimental atherosclerosis. Part 4. Inhibition of atherosclerosis in vivo and thromboxane synthesis and platelet aggregation in vitro. , 1979, Atherosclerosis.